U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Ovarian Clear Cell Adenocarcinoma

MedGen UID:
1667954
•Concept ID:
C4727398
•
Neoplastic Process

Definition

The reemergence of ovarian clear cell adenocarcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Ovarian Clear Cell Adenocarcinoma

Professional guidelines

PubMed

Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD
Gynecol Oncol 2021 Sep;162(3):741-750. Epub 2021 Jul 8 doi: 10.1016/j.ygyno.2021.06.033. PMID: 34247767
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K, Hamanishi J, Matsuo K, Hasegawa K
Gynecol Oncol 2018 Nov;151(2):381-389. Epub 2018 Sep 12 doi: 10.1016/j.ygyno.2018.09.001. PMID: 30217369Free PMC Article
Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M, Tsuda H, Sugiyama T
J Exp Clin Cancer Res 2012 Jun 1;31(1):53. doi: 10.1186/1756-9966-31-53. PMID: 22655678Free PMC Article

Recent clinical studies

Etiology

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS
Int J Gynecol Cancer 2020 Aug;30(8):1239-1242. Epub 2020 Jun 25 doi: 10.1136/ijgc-2020-001604. PMID: 32591370Free PMC Article
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N
Int J Gynecol Cancer 2006 Jan-Feb;16(1):52-6. doi: 10.1111/j.1525-1438.2006.00289.x. PMID: 16445610

Diagnosis

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS
Int J Gynecol Cancer 2020 Aug;30(8):1239-1242. Epub 2020 Jun 25 doi: 10.1136/ijgc-2020-001604. PMID: 32591370Free PMC Article

Therapy

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS
Int J Gynecol Cancer 2020 Aug;30(8):1239-1242. Epub 2020 Jun 25 doi: 10.1136/ijgc-2020-001604. PMID: 32591370Free PMC Article
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N
Int J Gynecol Cancer 2006 Jan-Feb;16(1):52-6. doi: 10.1111/j.1525-1438.2006.00289.x. PMID: 16445610

Prognosis

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS
Int J Gynecol Cancer 2020 Aug;30(8):1239-1242. Epub 2020 Jun 25 doi: 10.1136/ijgc-2020-001604. PMID: 32591370Free PMC Article
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.
Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N
Int J Gynecol Cancer 2006 Jan-Feb;16(1):52-6. doi: 10.1111/j.1525-1438.2006.00289.x. PMID: 16445610

Clinical prediction guides

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY, Heong V, Ow S, Chay WY, Kim HS, Choi CH, Goss G, Goh JC, Tai BC, Lim DG, Kaliaperumal N, Au VB, Connolly JE, Kim JW, Friedlander M, Kim K, Tan DS
Int J Gynecol Cancer 2020 Aug;30(8):1239-1242. Epub 2020 Jun 25 doi: 10.1136/ijgc-2020-001604. PMID: 32591370Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...